Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 4/20 | 0.80 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | HTR3B | O95264 | 1/20 | 0.50 |
| ▸ | HTR3A | P46098 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.50 |
| ▸ | PIK3CG | P48736 | 3/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | CDC7 | O00311 | 10/20 | 0.46 |
| ▸ | DBF4 | Q9UBU7 | 10/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1883506 | 0.91 | PIK3CD (0.84) | PIK3CDMAPTHTR3EMEN1HTR3B | |
| SCHEMBL3714011 | 0.90 | PIK3CD (1.00) | PIK3CDMAPTHTR3EMEN1HTR3B | |
| SCHEMBL1876878 | 0.88 | PIK3CD (0.79) | PIK3CDMAPTHTR3EMEN1HTR3B | |
| SCHEMBL1880566 | 0.87 | PIK3CD (0.84) | PIK3CDMAPTHTR3EMEN1HTR3B | |
| SCHEMBL1880412 | 0.85 | PIK3CD (0.88) | PIK3CDMAPTHTR3EMEN1HTR3B | |
| SCHEMBL1887394 | 0.85 | PIK3CD (0.88) | PIK3CDMAPTHTR3EMEN1HTR3B | |
| SCHEMBL1882801 | 0.85 | PIK3CD (0.88) | PIK3CDMAPTHTR3EMEN1HTR3B | |
| SCHEMBL1888908 | 0.83 | PIK3CD (0.84) | PIK3CDMAPTHTR3EMEN1HTR3B | |
| SCHEMBL1882405 | 0.82 | PIK3CD (0.79) | PIK3CDMAPTHTR3EMEN1HTR3B | |
| SCHEMBL1885617 | 0.82 | PIK3CD (0.84) | PIK3CDMAPTHTR3EMEN1HTR3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8399483-B2 | Quinoxaline and quinoline derivatives as kinase inhibitors | UCB PHARMA S.A. (BE) | 2013-03-19 | — | — | US | disclosed |
| US-20110105508-A1 | QUINOXALINE AND QUINOLINE DERIVATIVES AS KINASE INHIBITORS | UCB PHARMA, S.A. (BE) | 2011-05-05 | — | — | US | disclosed |
| EP-2231641-A2 | QUINOXALINE AND QUINOLINE DERIVATIVES AS KINASE INHIBITORS | UCB Pharma, S.A. (BE) | 2010-09-29 | — | — | EP | disclosed |
| WO-2009081105-A2 | QUINOXALINE AND QUINOLINE DERIVATIVES AS KINASE INHIBITORS | UCB PHARMA S.A. (BE) | 2009-07-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105508-A1 | QUINOXALINE AND QUINOLINE DERIVATIVES AS KINASE INHIBITORS | PDXK, PDPK1, PIKFYVE | PIK3CD 8/4885MAPT 2318/4885HTR3E 1573/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.